
JPXHealthcareDrug Manufacturers - General
Latest quote
¥11,425
+¥160 · +1.42%
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.
Latest quote
¥11,425
+¥160 · +1.42%
Regular session · JST · Market data may be delayed.
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.
Day range
Current ¥11,425
52-week range
Current ¥11,425
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.47T JPY | 2.33T JPY | 2.02T JPY | 1.74T JPY | 1.5T JPY |
| Cost of goods sold | 699.12B JPY | 660.43B JPY | 611.22B JPY | 569.5B JPY | 495.03B JPY |
| Gross profit | 1.77T JPY | 1.67T JPY | 1.41T JPY | 1.17T JPY | 1T JPY |
| Research and development | 352.84B JPY | 314.23B JPY | 307.8B JPY | 275.23B JPY | 232.3B JPY |
| Selling, general, and administrative | 1T JPY | 958.35B JPY | 807.36B JPY | 724.13B JPY | 622.33B JPY |
| Operating expenses | 1.36T JPY | 1.27T JPY | 1.27T JPY | 1.02T JPY | 854.63B JPY |
| Interest income | 15.7B JPY | 21.08B JPY | 9.57B JPY | 28.69B JPY | 13.98B JPY |
| Interest expense | 27.03B JPY | 8.79B JPY | 6.52B JPY | 6.06B JPY | 4.84B JPY |
| Depreciation and amortization | 116.17B JPY | 107.98B JPY | 93.7B JPY | 93.76B JPY | 84.86B JPY |
| Operating income | 412.43B JPY | 396.85B JPY | 139.61B JPY | 150.32B JPY | 148.62B JPY |
| Net income | 363.15B JPY | 343.12B JPY | 121.62B JPY | 133.91B JPY | 125.46B JPY |
Company facts updated Sep 15, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
¥140
2025 complete year+40.0% since 2021
2026 partial: ¥100
¥100
2,021
¥100
2,022
¥110
2,023
¥120
2,024
¥140
2,025
¥100
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
DividendUpcoming | Dec 29, 2026 | ¥100Semi-Annual | Dec 31, 2026 | Dec 29, 2026 |
Dividend | Jun 29, 2026 | ¥100Semi-Annual | Jun 30, 2026 | Sep 1, 2026 |
Dividend | Dec 29, 2025 | ¥70.00Semi-Annual | Dec 31, 2025 | Mar 30, 2026 |
Dividend | Jun 27, 2025 | ¥70.00Semi-Annual | Jun 30, 2025 | Sep 1, 2025 |
Dividend | Dec 27, 2024 | ¥60.00Semi-Annual | Dec 31, 2024 | Mar 31, 2025 |
Dividend | Jun 27, 2024 | ¥60.00Semi-Annual | Jun 30, 2024 | Sep 2, 2024 |
Ex-dividend Dec 29, 2026
¥100
Semi-Annual
Record Dec 31, 2026 · Payment Dec 29, 2026
Ex-dividend Jun 29, 2026
¥100
Semi-Annual
Record Jun 30, 2026 · Payment Sep 1, 2026
Ex-dividend Dec 29, 2025
¥70.00
Semi-Annual
Record Dec 31, 2025 · Payment Mar 30, 2026
Ex-dividend Jun 27, 2025
¥70.00
Semi-Annual
Record Jun 30, 2025 · Payment Sep 1, 2025
Ex-dividend Dec 27, 2024
¥60.00
Semi-Annual
Record Dec 31, 2024 · Payment Mar 31, 2025
Ex-dividend Jun 27, 2024
¥60.00
Semi-Annual
Record Jun 30, 2024 · Payment Sep 2, 2024
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core TOPIX ETF1475.T14.26B0.49%2.9T JPY0.05%¥415.1-0.43%
iShares Core Nikkei 225 ETF1329.T12.13B0.59%2.05T JPY0.05%¥6,575-0.26%
iShares JPX-Nikkei 400 ETF1364.T4.35B0.74%591.76B JPY0.05%¥3,711-0.54%
Vanguard Total International Stock ETFVXUS452.59M0.07%646.2B USD0.05%$86.04-1.26%
Vanguard FTSE Developed Markets ETFVEA301.45M0.09%315B USD0.03%$71.72-1.34%
iShares Core MSCI EAFE ETFIEFA233.3M0.12%194.75B USD0.07%$98.68-0.82%
iShares MSCI Japan ETFEWJ135.42M0.58%23.64B USD0.49%$97.58-0.99%
JPMorgan BetaBuilders Japan ETFBBJP120.86M0.61%19.7B USD0.19%$78.82-0.92%
iShares Core TOPIX ETF1475.T
iShares Core Nikkei 225 ETF1329.T
iShares JPX-Nikkei 400 ETF1364.T
Vanguard Total International Stock ETFVXUS
Vanguard FTSE Developed Markets ETFVEA
iShares Core MSCI EAFE ETFIEFA
iShares MSCI Japan ETFEWJ
JPMorgan BetaBuilders Japan ETFBBJPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.